Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jul;89(7):806-8.
doi: 10.1136/bjo.2004.054239.

The use of low dose methotrexate in children with chronic anterior and intermediate uveitis

A R Malik  1 , C Pavesio
Affiliations

The use of low dose methotrexate in children with chronic anterior and intermediate uveitis

A R Malik et al. Br J Ophthalmol. 2005 Jul.

Abstract

Aim: To assess the efficacy of low dose methotrexate (MTX) therapy for children with chronic anterior and intermediate uveitis.

Methods: A retrospective case review of 10 children who received MTX for chronic uveitis at a tertiary referral centre was performed. The following data were recorded for each patient: age, sex, race, duration of uveitis, primary diagnosis, anatomical localisation of uveitis, corticosteroid therapy, dose range of MTX, duration of MTX therapy, and side effects of MTX therapy. Several clinical parameters were evaluated to study the effect of MTX. These included visual acuity, anterior chamber inflammation, and topical and oral corticosteroid requirement.

Results: After MTX VA of 6/6 or better was present in 100% right eyes and 80% left eyes (p = 0.055 and p = 0.016, respectively). Anterior chamber inflammation decreased in 60% of children after MTX (p = 0.0168). The requirement of topical steroid decreased from a mean of 5.6 times a day before MTX to 1.5 times a day after MTX (p = 0.005). The dose of oral steroid decreased from a mean of 18 mg per day to 2.85 mg per day (p = 0.012). The most common adverse effect was nausea (20%). No patient required discontinuation of MTX because of side effects.

Conclusion: MTX is effective and safe for chronic anterior and intermediate uveitis in children. An increase awareness of its efficacy is required among paediatricians and ophthalmologists to prevent sight threatening complication of chronic uveitis and its treatment with long term use of steroids.

PubMed Disclaimer

References

    1. Tugal-Tutkin I, Havrlikova K, Power WJ, et al. Changing patterns in uveitis in childhood. Ophthalmology 1996;103:375–83. - PubMed
    1. Kanski JJ, Shun-Shin A. Systemic uveitis syndromes in childhood. An analysis of 340 cases. Ophthalmology 1984:91247–51. - PubMed
    1. Solomon SD, Cunningham ET Jr. Use of corticosteroids and non-corticosteroid immunosuppressive agents in patients with uveitis. Comprehensive Ophthalmology Update 2001;1:273–86.
    1. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis, fundamentals and clinical practice. 2nd ed. St Louis: Mosby, 1996:97–129.
    1. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492–513. - PubMed

MeSH terms